Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

Hormone Replacement Therapy MarketThe global hormone replacement therapy (HRT) market is poised for steady growth, with a projected compound annual growth rate (CAGR) of 3.5%. From an estimated market ...

Global growth is projected at 3.3 percent both in 2025 and 2026, below the historical (2000–19) average of 3.7 percent. The forecast for 2025 is broadly unchanged from that in the October 2024 World ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

For instance, in October 2021, Pfizer, Inc. and OPKO Health, Inc. updated their Biologics License Application to the U.S. FDA for the investigational drug somatropin to treat growth hormone ...

Contract Pharmaceutical Manufacturing Market is expected to reach USD 403.45 Bn by 2031, exhibiting a compound annual growth rate of 9.7% from 2024 to 2031. BURLINGAME, CA, UNITED STATES ...

However, that would still represent just 1% penetration of the company's estimated $100 billion addressable market, which suggests it has a long growth runway ahead. Confluent had 5,680 customers ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...